Aquestive Q2 revenue up 52% to $20.1M; narrows net loss; raises FY guidance

Aquestive Therapeutics, Inc.

2024-Q2 EPS reported -$0.19 revenue$32,152,000

Total revenue $20.1M vs $13.2M YoY; net loss $2.7M ($0.03/sh) improves from $5.8M loss.
Non-GAAP adjusted EBITDA positive $1.8M vs -$3.3M; cash $89.9M.
Raises FY24 revenue guidance to $57-60M (prev. $48-51M); adj. EBITDA loss guidance narrowed to $20-23M.
Anaphylm NDA submission on track for Q1 2025; launch expected end 2025/early 2026.
Libervant expanded to ages 2-5; national retail distribution expected Q4 2024; epinephrine prodrug investor day planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.